Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...
Cristina Suárez describes LITESPARK-033, a phase 3 trial addressing an unmet need in patients who progress during or within 24 months after adjuvant pembrolizumab for clear cell renal cell carcinoma.
The majority of bladder cancers are diagnosed as non-muscle invasive (NMIBC), with 90% over the age of 55. Although the incidence of several malignancies is increasing among younger adults in whom ...
(UroToday.com) The 2025 SUO annual meeting featured a kidney session and a presentation by Dr. Brian Shuch discussing ZIRCON-X and the impact of 89 Zr-girentuximab PET/CT versus conventional imaging ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical trial updates session and presentation by Dr. Désirée Deandreis discussing the PEACE-6 PR trial. Recently, prostate cancer is ...
(UroToday.com) The European Association of Urology (EAU) 2026 Annual Congress was host to an advanced prostate cancer session hosted jointly by the Advanced Prostate Cancer Consensus Conference (APCCC ...
The shape and material of external urine collection devices (EUCD) have changed over the past 20 years. Historically, most EUCDs were made from latex that allowed for flexibility but also increased ...
(UroToday.com) The 2025 EAU annual meeting featured a game changer session and a presentation by Dr. James Catto discussing surgical outcomes and neoadjuvant safety with perioperative durvalumab for ...
(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a presentation by Dr. Brian Rini discussing the 5-year analysis of KEYNOTE-426, assessing pembrolizumab + ...
SNMMI 2025: Development of PSMA Targeting Radioligand 161Tb-LNC1011 for Prostate Cancer Theranostics
(UroToday.com) The 2025 SNMMI annual meeting featured a radiotheranostics session and a presentation by Dr. Xuejen Wen discussing the development of PSMA targeting radioligand 161 Tb-LNC1011 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results